| Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug | 07/01 09:45 | zacks.com |
| Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU | 06/28 06:57 | globenewswire.com |
| Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study | 06/11 10:51 | zacks.com |
| Why Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report? | 06/06 12:36 | zacks.com |
| Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference | 06/05 07:00 | globenewswire.com |
| Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data | 05/27 13:36 | zacks.com |
| Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress | 05/24 10:00 | globenewswire.com |
| Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat | 05/07 12:21 | zacks.com |
| Apellis Pharmaceuticals (APLS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates | 05/07 10:36 | zacks.com |
| Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates | 05/07 09:16 | zacks.com |